Advancing Drug Development through Molecular Imaging (ADDMI) Interest Group: Strategic Directions


Strategic Directions
Address the pipeline issue for advancing drug development through molecular imaging

  • Encourage and foster multidisciplinary research towards development of clinically validated molecular imaging based companion diagnostics (MICOD)
  • Provide a platform for productive discussions around development of molecular imaging companion diagnostics and its challenges
  • Attract academics, industry professionals, CROs,  Biotechs and clinicians to pursue a common goal of developing MICOD and its integration in drug development

Help facilitate the successful development of MICOD

  • Encourage and reward innovative science that helped development of MICOD
  • Provide a platform to address Clinical manufacturing issues and Phase 1 clinical trials
  • Establish MICOD/WMIS as a ‘central body’ to help address regulatory and reimbursement issues related to MICOD